The neurophysiological effects of single-dose theophylline in patients with chronic stroke: A double-blind, placebo-controlled, randomized cross-over study

被引:3
|
作者
Schambra, Heidi M. [1 ,2 ]
Martinez-Hernandez, Isis E. [1 ,2 ]
Slane, Kevin J. [3 ]
Boehme, Amelia K. [3 ]
Marshall, Randolph S. [3 ]
Lazar, Ronald M. [3 ]
机构
[1] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA
[2] Columbia Univ, Med Ctr, Dept Rehabil & Regenerat Med, Motor Performance Lab, New York, NY USA
[3] Columbia Univ, Med Ctr, Richard & Jenny Levine Cerebral Localizat Lab, Dept Neurol, New York, NY USA
关键词
Recovery of function; transcranial magnetic stimulation; cerebral infarction; motor cortex; homeostasis; LONG-TERM POTENTIATION; HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; GAMMA-AMINOBUTYRIC ACID; CORTICAL EXCITABILITY; INTERHEMISPHERIC INHIBITION; CORTICOCORTICAL INHIBITION; INTRACORTICAL INHIBITION; OLFACTORY CORTEX; RECOVERY;
D O I
10.3233/RNN-160657
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Reducing inhibitory neurotransmission with pharmacological agents is a potential approach for augmenting plasticity after stroke. Previous work in healthy subjects showed diminished intracortical inhibition after administration of theophylline. Objective: We assessed the effect of single-dose theophylline on intracortical and interhemispheric inhibition in patients with chronic stroke, in a double-blind, placebo-controlled, cross-over study. Methods: Eighteen subjects were randomly administered 300 mg of extended-release theophylline or placebo. Immediately and 5 hours following administration, transcranial magnetic stimulation was used to assess bihemispheric resting motor threshold, short-interval intracortical inhibition, long-interval intracortical inhibition, and interhemispheric inhibition. Adverse effects on cardiovascular, neurological, and motor performance outcomes were also surveilled. Change between morning and afternoon sessions were compared across conditions. One week later, patients underwent the same assessments after crossing over to the opposite experimental condition. Subjects and investigators were blinded to the experimental condition during data acquisition and analysis. Results: For both hemispheres, changes in intracortical or interhemispheric neurophysiology were comparable under theophylline and placebo conditions. Theophylline induced no adverse neurological, cardiovascular, or motor performance effects. For both conditions and hemipsheres, the baseline level of inhibition inversely correlated with its change between sessions: less baseline inhibition (i.e. disinhibition) was associated with a strengthening in inhibition over the day, and vice versa. Conclusion: A single dose of theophylline is well-tolerated by patients with chronic stroke, but does not alter cortical excitability. The inverse relationship between baseline inhibition and its change suggests the existence of a homeostatic process. The lack of effect on cortical inhibition may be related to an insufficiently long exposure to theophylline, or to differential responsiveness of disinhibited neural circuitry in patients with stroke.
引用
收藏
页码:799 / 813
页数:15
相关论文
共 50 条
  • [1] RIOCIGUAT FOR THE TREATMENT OF RAYNAUD'S PHENOMENON: A SINGLE-DOSE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSS-OVER STUDY (DIGIT)
    Huntgeburth, M.
    Kiessling, J.
    Weimann, G.
    Kiepsel, V.
    Saleh, S.
    Hunzelmann, N.
    Rosenkranz, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 588 - 588
  • [2] Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study
    G. S. Ungvari
    Helen F. K. Chiu
    Lok Yee Chow
    Benjamin S. T. Lau
    Wai Kwong Tang
    [J]. Psychopharmacology, 1999, 142 : 393 - 398
  • [3] Riociguat for the Treatment of Raynaud’s Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT)
    Michael Huntgeburth
    Johannes Kießling
    Gerrit Weimann
    Verena Wilberg
    Soundos Saleh
    Nicolas Hunzelmann
    Stephan Rosenkranz
    [J]. Clinical Drug Investigation, 2018, 38 : 1061 - 1069
  • [4] Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT)
    Huntgeburth, Michael
    Kiessling, Johannes
    Weimann, Gerrit
    Wilberg, Verena
    Saleh, Soundos
    Hunzelmann, Nicolas
    Rosenkranz, Stephan
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1061 - 1069
  • [5] EFFECTS OF CISAPRIDE ON CONSTIPATION IN PARAPLEGIC PATIENTS - A PLACEBO-CONTROLLED RANDOMIZED DOUBLE-BLIND CROSS-OVER STUDY
    DEBOTH, PSM
    DEGROOT, GH
    SLOOTMAN, HR
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1992, 4 (12) : 1013 - 1017
  • [6] Riociguat for the Treatment of Raynaud's Phenomenon: A Single-dose, Double-blind, Randomised, Placebo-controlled Cross-over Study (DIGIT)
    Huntgeburth, Michael
    Kiessling, Johannes
    Weimann, Gerrit
    Kiepsel, Verena
    Saleh, Soundos
    Hunzelmann, Nicolas
    Rosenkranz, Stephan
    [J]. CIRCULATION, 2015, 132
  • [7] Lorazepam for chronic catatonia: a randomized, double blind, placebo-controlled cross-over study
    Ungvari, GS
    Chiu, HFK
    Chow, LY
    Lau, BST
    Tang, WK
    [J]. PSYCHOPHARMACOLOGY, 1999, 142 (04) : 393 - 398
  • [8] CYCLANDELATE IN DIABETIC NEUROPATHY - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSS-OVER STUDY
    HEIMANS, JJ
    DRUKARCH, B
    MATTHAEI, I
    IJFF, GA
    BERTELSMANN, FW
    STRIJERS, RLM
    NAUTA, J
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 (06): : 483 - 486
  • [9] Levodopa for chronic neck pain: A cross-over double-blind, placebo-controlled study
    Marziniak, M
    Guralnik, V
    Dillmann, U
    Becker, G
    [J]. MOVEMENT DISORDERS, 2004, 19 : S393 - S394
  • [10] The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
    Michael Huntgeburth
    Johannes Kießling
    Gerrit Weimann
    Verena Kiepsel
    Soundos Saleh
    Nicolas Hunzelmann
    Stephan Rosenkranz
    [J]. BMC Pharmacology and Toxicology, 16 (Suppl 1)